Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

CALGARY, June 5, 2017 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announced that a patent covering its clinical compound, ZEN-3694, has been issued by the United States Patent and Trademark Office (USPTO). The patent is held by Zenith Epigenetics Ltd. (Zenith Epigenetics), a wholly owned subsidiary of Zenith. ZEN-3694, a small molecule BET bromodomain inhibitor, is in clinical development for metastatic castrate resistant prostate cancer as a single agent and in combination with enzalutamide. In addition, two other patents, held by Zenith Epigenetics, have recently been issued by the USPTO, adding to Zenith Epigenetics' growing patent estate of BET bromodomain inhibitors.

"We are extremely pleased with the issuance of this key patent covering ZEN-3694. It strengthens Zenith's position as a leader in the field of Epigenetics, and BET bromodomain inhibition, in particular,"   stated Donald McCaffrey, President & Chief Executive Officer.

2017 BIO International Convention Presentation Details

Zenith is scheduled to participate in the upcoming BIO International Convention in San Diego, CA. Mr. Donald McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.

Presentation Details:

Date: Tuesday, June 20^th
Time: 3:30pm PT
Duration: ~15 minutes
Location: Company Presentation Theatre 3

The presentation will be available on the Company website, on the Presentations & Publications page immediately prior to the scheduled presentation time.

About Zenith

Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics.  Zenith Epigenetics Ltd.'s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC).

SOURCE Zenith Capital Corp.

Related Links

www.zenithepigenetics.com